ARTICLE | Emerging Company Profile
Nine Square: taking aim at organelle function in movement disorders with computation and imaging
The Apple Tree-founded UCSF spinout is developing CNS-targeted small molecules against genetically defined targets
May 14, 2021 8:56 PM UTC
By combining technologies from two UCSF groups, Apple Tree Partners-built Nine Square aims to develop small molecules that overcome loss of organelle function in movement disorders.
Nine Square Therapeutics Inc. made its debut last July with a $50 million series A round. The company is using computational chemistry and physics-based modeling from the lab of serial entrepreneur Matthew Jacobson to identify small molecule candidates, and testing their effects in disease-relevant cell types using quantitative single-cell phenotyping technology from the lab of Steven Altschuler and Lani Wu. ...